Novacyt Saham

Novacyt EBITDA

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari Novacyt (ALNOV.PA) pada 15 Agu 2026 adalah -7,49 Juta. GBP. Tahun sebelumnya, EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) adalah -10,38 Juta. GBP — perubahan sebesar -27,85% (lebih tinggi).

EBITDA

-7,49 Juta.GBP

YoY

-27,85%

Terakhir Diperbarui:

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari Novacyt adalah 2026 -7,49 Juta. GBP. EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari Novacyt adalah 2025 -10,38 Juta. GBP. Menurun -27,85% lebih tinggi dibandingkan dengan tahun sebelumnya.
Access this data via the Eulerpool API

Novacyt Analisis saham

Apa yang dilakukan Novacyt? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt adalah salah satu perusahaan paling populer di Eulerpool.

Pertanyaan yang Sering Diajukan tentang saham Novacyt

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) Novacyt adalah -7,49 Juta. GBP pada tahun 2026.

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari Novacyt berubah dari -10,38 Juta. GBP menjadi -7,49 Juta. GBP, mewakili perubahan -27,85%. Nilainya lebih tinggi daripada tahun sebelumnya.

Di Eulerpool Anda dapat menemukan perkembangan historis lengkap EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) Novacyt sejak 2006 – dengan nilai tahunan, bagan, dan analisis detail.

EBITDA mengukur kinerja operasional sebelum dampak struktur keuangan, lingkungan pajak, dan biaya penyusutan non-kas.

EBITDA = EBIT + Penyusutan & Amortisasi

GBP EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) adalah faktor kunci bagi investor. Perubahan metrik ini dapat menunjukkan fundamental yang membaik atau memburuk, secara langsung memengaruhi harga saham. Di Eulerpool, Anda dapat melacak Novacyt EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) secara historis dan real-time.

Access this data via the Eulerpool API

Laporan Laba Rugi — Novacyt

Semua Metrik Kunci — Novacyt